This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sinha, R. Articles by Shin, D. M. Search for Related Content PubMed PubMed Citation Articles by Sinha, R. Articles by Shin, D. M. Related Collections Therapeutics and Targets Therapeutics and Targets: Pharmacology and Toxicology

Review

Nanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery

¹ Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine and ² Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia

Requests for reprints: Dong M. Shin, Department of Hematology and Oncology, Winship Cancer Institute, Emory University School of Medicine, 1365-C Clifton Road, Room 3090, Atlanta, GA 30322. Phone: 404-778-5990; Fax: 404-778-5520. E-mail: dong.shin{at}emoryhealthcare.org

Nanotechnology refers to the interactions of cellular and molecular components and engineered materials—typically, clusters of atoms, molecules, and molecular fragments into incredibly small particles—between 1 and 100 nm. Nanometer-sized particles have novel optical, electronic, and structural properties that are not available either in individual molecules or bulk solids. The concept of nanoscale devices has led to the development of biodegradable self-assembled nanoparticles, which are being engineered for the targeted delivery of anticancer drugs and imaging contrast agents. Nanoconstructs such as these should serve as customizable, targeted drug delivery vehicles capable of ferrying large doses of chemotherapeutic agents or therapeutic genes into malignant cells while sparing healthy cells. Such "smart" multifunctional nanodevices hold out the possibility of radically changing the practice of oncology, allowing easy detection and then followed by effective targeted therapeutics at the earliest stages of the disease. In this article, we briefly discuss the use of bioconjugated nanoparticles for the delivery and targeting of anticancer drugs. [Mol Cancer Ther 2006;5(8):1909–17]

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 3/16/06; revised 5/18/06; accepted 6/ 7/06.

This article has been cited by other articles:

				P. R. Hall, B. Hjelle, D. C. Brown, C. Ye, V. Bondu-Hawkins, K. A. Kilpatrick, and R. S. Larson Multivalent Presentation of Antihantavirus Peptides on Nanoparticles Enhances Infection Blockade Antimicrob. Agents Chemother., June 1, 2008; 52(6): 2079 - 2088. [Abstract] [Full Text] [PDF]

				Z. Liu, C. Davis, W. Cai, L. He, X. Chen, and H. Dai Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy PNAS, February 5, 2008; 105(5): 1410 - 1415. [Abstract] [Full Text] [PDF]

				D. M. Shin Nanotechnology: A Novel Approach to Drug Delivery in Cancer Therapeutics Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 3 - 8. [Full Text] [PDF]